Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a post on X:
“Day 1 of IASLC WCLC25 with a lot of new data to come out tomorrow morning at the Presidential Symposium on management of Biomarker-driven lung cancer:
- FLAURA2 OS of Osimertinib +chemo in 1L EGFR
- ACROSS2 Aumolertinib +chemo in 1L EGFR
- HARMONI Ivonescimab + chemo post EGFR TKI
- ARROS-1 Zidesamtinib post ROS1 TKI
- ALCHEMIST Adjuvant Crizotinib for ALK+”
✅Day1 of @IASLC #WCLC25 with a lot of new data to come out tomorrow morning at the Presidential Symposium on mgmt of Biomarker-driven lung cancer🫁:
🎯#FLAURA2 OS of Osimertinib +chemo in 1L EGFR
🎯#ACROSS2 Aumolertinib +chemo in 1L EGFR
🎯#HARMONI Ivonescimab + chemo post EGFR… pic.twitter.com/WnKZQ8cAvq— Dr. Estela Rodriguez (@Latinamd) September 7, 2025
Yvonne Diaz, Director of Global Media Relations and Social Media at EY and Co-Founder of Oncogene Cancer Research, shared her post adding:
“On now at IASLC WCLC25.
Look forward to commenting on these important abstracts at today’s press conference. For patients, every new trial, every incremental step forward, means time, hope, and options for real people.”
More from WCLC25 on OncoDaily.